Zobrazeno 1 - 10
of 208
pro vyhledávání: '"Andrew Haydon"'
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 1, Pp 67-72 (2024)
NUT carcinomas (NCs) are a group of rare tumors that can occur anywhere in the body and are defined by the fusion of the nuclear protein in testis (NUTM1) resulting in increased transcription of proto-oncogenes. NCs have a poor prognosis that varies
Externí odkaz:
https://doaj.org/article/3cb038dcb4134b309adfab6871b4ee9e
Autor:
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102564- (2024)
Externí odkaz:
https://doaj.org/article/377d8aad4882472db54c2cd4b6fbb9b1
Autor:
Andrew Haydon, John Powderly, Timothy Wyant, James Vasselli, Drew Rasco, Meredith McKean, Elizabeth Ahern, Sophia Frentzas, Andrew Weickhardt, Inbar Amit, Aron Knickerbocker, Yanay Ofran, Paul de Souza, Jenny Tang, Lori Richards
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/cac7820b4bd0445e9e32670fae38d1ab
Autor:
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty
Publikováno v:
EClinicalMedicine, Vol 65, Iss , Pp 102290- (2023)
Summary: Background: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We aimed to
Externí odkaz:
https://doaj.org/article/43eb9c43eb9a4af8ab0b21da71b61e89
Autor:
Charlie Wang, Sophia Zoungas, Mabel Yan, Rory Wolfe, Andrew Haydon, Mark Shackleton, Mark Voskoboynik, Maggie Moore, Miles C. Andrews, Stephen J. Nicholls, Victoria Mar
Publikováno v:
Cardio-Oncology, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract Background Immune checkpoint inhibitors (ICI) are associated with immune-mediated adverse effects, potentially involving any organ. ICI has also been associated with an increased risk of cardiovascular disease in cancer populations. Objectiv
Externí odkaz:
https://doaj.org/article/9d58bc9253b64ae0b4b56c4e9713f2dc
Autor:
Wei Wang, Andrew Haydon, Rebecca Johnson, Elisabeth Livingstone, Zeynep Eroglu, Grant A McArthur, Douglas B Johnson, Prachi Bhave, Georgina Long, Adnan Khattak, Matteo S Carlino, Johanna Mangana, Katharina Kahler, Angela Hong, Serigne N Lo, Hui-Ling Yeoh, Alexander Maxwell Menzies, Ozgecan Dulgar, Georg C Lodde, Axel Hausschild
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background In patients with stage III melanoma, despite surgical resection and adjuvant systemic therapy, locoregional recurrences still occur. The randomized, phase III Trans-Tasman Radiation Oncology Group (TROG) 02.01 trial demonstrated that adjuv
Externí odkaz:
https://doaj.org/article/35448e0e51c54b988eb95ba45ce8d0d2
Autor:
Matthew Burge, David Goldstein, Andrew Haydon, Nick Pavlakis, Charlotte Lemech, Edward Hammond, Darryn Bampton, Keith Dredge, Michael P Brown, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Pixatimod is a unique activator of the Toll-like Receptor 9 pathway. This phase I trial evaluated safety, efficacy and pharmacodynamics of pixatimod and PD-1 inhibitor nivolumab in immunologically cold cancers.Methods 3+3 dose escalation w
Externí odkaz:
https://doaj.org/article/9084358ebd5841eb853afac834f15155
Autor:
Jaidyn Muhandiramge, Erica T. Warner, John R. Zalcberg, Andrew Haydon, Galina Polekhina, Gijsberta J. van Londen, Peter Gibbs, Wendy B. Bernstein, Jeanne Tie, Jeremy L. Millar, Victoria J. Mar, John J. McNeil, Robyn L. Woods, Suzanne G. Orchard
Publikováno v:
Cancers, Vol 15, Iss 4, p 1017 (2023)
Introduction: Cancer treatment planning in older adults is complex and requires careful balancing of survival, quality of life benefits, and risk of treatment-related morbidity and toxicity. As a result, treatment selection in this cohort tends to di
Externí odkaz:
https://doaj.org/article/a7f0246df8694058b4359d9159d04648
Autor:
Matthew Burge, David Goldstein, Andrew Haydon, Nick Pavlakis, Michael Brown, Charlotte Lemech, Edward Hammond, Darryn Bampton, Keith Dredge, Amanda Stanley, Lucie Leveque-ElMouttie, Grace Chojnowski
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/707ab3742ab34661a168c0e1852c01c0
Autor:
Matthew Burge, David Goldstein, Andrew Haydon, Nick Pavlakis, Michael Brown, Charlotte Lemech, Edward Hammond, Darryn Bampton, Keith Dredge, Nigel Waterhouse, Amanda Stanley, Lucie Leveque-ElMouttie, Grace Chojnowski, Andrew Clouson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/28156c09a15e41f3a51704b1a003571b